Quality ID #418 (NQF 0053): Osteoporosis Management in Women Who Had a Fracture
– National Quality Strategy Domain: Effective Clinical Care
– Meaningful Measure Area: Management of Chronic Conditions

**2019 COLLECTION TYPE:**
MIPS CLINICAL QUALITY MEASURES (CQMS)

**MEASURE TYPE:**
Process

**DESCRIPTION:**
The percentage of women age 50-85 who suffered a fracture in the six months prior to the performance period through June 30 of the performance period and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis in the six months after the fracture.

**INSTRUCTIONS:**
This measure is to be submitted after each occurrence of a fracture during the six months prior to the performance period through June 30 of the performance period. It is anticipated that Merit-based Incentive Payment System (MIPS) eligible clinicians who treat any fracture except fractures of the finger, toe, face or skull will submit this measure. Each occurrence of a fracture is identified by either an ICD-10-CM diagnosis code for fracture and a CPT service code OR an ICD-10-CM diagnosis code for a fracture and a CPT procedure code for surgical treatment of fractures.

**NOTE:** Patients with any fracture except fractures of the finger, toe, face or skull should have a bone mineral density (BMD) measurement performed or pharmacologic therapy prescribed. The management (BMD performed or pharmacologic therapy prescribed) should occur within six months of the fracture. If multiple fractures occurring on the same date of service are submitted on the same claim form, only one instance of submission will be counted. Claims data will be analyzed to determine unique occurrences. Patients already receiving pharmacologic therapy would automatically meet the intent of this measure.

**Measure Submission Type:**
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

The intent of the exclusion for individuals age 65 and older residing in long-term care facilities, including nursing homes, is to exclude individuals who may have limited life expectancy and increased frailty where the benefit of the process may not exceed the risks. This exclusion is not intended as a clinical recommendation regarding whether the measures process is inappropriate for specific populations, instead the exclusions allows clinicians to engage in shared decision making with patients about the benefits and risks of screening when an individual has limited life expectancy.

**DENOMINATOR:**
Women who experienced a fracture, except fractures of the finger, toe, face or skull, during the six months prior to the performance period through June 30 of the performance period

Option 1 - Denominator Criteria (Eligible Cases):
Patients aged 50-85 years on date of encounter
AND
Diagnosis for any fracture except fractures of the finger, toe, face or skull (ICD-10-CM): M48.40XA, M48.41XA, M48.42XA, M48.43XA, M48.44XA, M48.45XA, M48.46XA, M48.47XA, M48.48XA, M80.00XA,
S72.465C, S72.466A, S72.466B, S72.466C, S72.471A,
S72.452C, S72.453A, S72.453B, S72.453C, S72.454A,
S72.435C, S72.436A, S72.436B, S72.436C, S72.441A,
S72.425C, S72.426A, S72.426B, S72.426C, S72.431A,
S72.422C, S72.423A, S72.423B, S72.423C, S72.424A,
S72.412C, S72.413A, S72.413B, S72.413C, S72.414A,
S72.352C, S72.353A, S72.353B, S72.353C, S72.354A,
S72.325C, S72.326A, S72.326B, S72.326C, S72.331A,
S72.302C, S72.309A, S72.309B, S72.309C, S72.312A,
Patient encounter during the performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, G0402

AND

DENOMINATOR EXCLUSIONS:
Patients who utilize hospice services any time during the measurement period: G9768

OR

Patient had a bone mineral density test in the past two years OR received osteoporosis medication or therapy in the past 12 months: G9769

OR

Patients age 65 or older in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code, 32, 33, 34, 54, or 56 any time during the measurement period: G9938

OR

Option 2 - Denominator Criteria (Eligible Cases):
Patients aged 50-85 years on date of encounter

AND


Option 2 - Denominator Criteria (Eligible Cases):
Patients aged 50-85 years on date of encounter

AND


AND

Patient procedure during the performance period (CPT): 22310, 22315, 22316, 22319, 22325, 22326, 22327, 22510, 22511, 22512, 22514, 25600, 25605, 25606, 25607, 25608, 27230, 27232, 27235, 27236, 27238, 27240, 27244, 27245, 27246, 27248

AND NOT

DENOMINATOR EXCLUSIONS:

Patients who utilize hospice services any time during the measurement period: G9768

OR

Patient had a bone mineral density test in the past two years OR received osteoporosis medication or therapy in the past 12 months: G9769

OR

Patients age 65 or older in Institutional Special Needs Plans (SNP) or residing in long-term care with

POS code 32, 33, 34, 54, or 56 any time during the measurement period: G9938
NUMERATOR:
Patients who received either a bone mineral density test or a prescription for a drug to treat osteoporosis in the six months after the fracture

Definitions:
Pharmacologic Therapy – U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, alendronate-cholecalciferol, ibandronate, risedronate, zoledronic acid, calcitonin, teriparatide, denosumab, and raloxifine.
Prescribed – May include prescription given to the patient for treatment of osteoporosis (as listed above) at one or more encounters during the performance period, or documentation that patient is already taking pharmacologic therapy for osteoporosis, as documented in the current medical list.
Bone Mineral Density (BMD)- A bone density test is an examination by either special x-rays or ultrasound to determine how much bone mineral content (calcium and other minerals) is present in any section of bone.

NUMERATOR NOTE: While the Central Dual Energy X-Ray Absorptiometry (DXA) is the most common measurement for measuring bone mineral density (BMD), for the purposes of submitting this measure, spinal densitometry x-ray, ultrasonography for densitometry, CT bone density axial and Peripheral Dual-energy X-Ray Absorptiometry (DXA) would meet performance and the intent of the measure and 3095F would be submitted.

Numerator Options:
Performance Met: Central Dual-energy X-Ray Absorptiometry (DXA) results documented (3095F)
OR
Performance Met: Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed (G8633)
OR
Performance Not Met: Central Dual energy X-ray absorptiometry (DXA) measurement was not performed, reason not otherwise specified (3095F with 8P)
OR
Performance Not Met: Pharmacologic therapy for osteoporosis was not prescribed, reason not given (G8635)

RATIONALE:
The intent of this measure is secondary prevention of fractures through the appropriate diagnosis and treatment of osteoporosis. Detecting osteoporosis and initiating treatment will help to prevent future fractures from occurring.

Future fractures, especially in the older population, can cause significant health issues, decline in function, and, in some cases lead to mortality.

CLINICAL RECOMMENDATION STATEMENTS:
Appropriate follow-up care for a fracture in post-menopausal women includes either 1) bone mineral density testing to assess whether a patient has osteoporosis or 2) receiving pharmacologic therapy to treat osteoporosis. This measure is based on guidelines and evidence that patients at high risk of fracture, including patients with a history of fragility fractures, should be screened for osteoporosis (USPSTF 2012, Nelson 2010, AACE 2010) and that patients who have a fragility fracture of the hip or spine should be provided with a treatment for osteoporosis (AACE 2010, Crandall 2012).

“The USPSTF recommends screening for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors.” (USPSTF 2011)
All postmenopausal women with a history of fracture without major trauma should receive a bone mineral density test to
test for osteoporosis (AACE 2010). Patients who have a history of fracture of the hip or spine also need pharmacologic
therapy to treat for osteoporosis. (AACE 2010; NOF 2014)

American Association of Clinical Endocrinologists (AACE). Medical Guidelines for Clinical Practice for the Diagnosis and
Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis, accessed April 25, 2014.

Osteoporosis

Preventive Services Task Force (USPSTF). Recommendations and Rationale: Screening for Osteoporosis in
Osteoporosis in Postmenopausal Women

COPYRIGHT:
This Physician Performance Measure (Measure) and related data specifications have been developed by the PCPI(R)
Foundation (PCPI(R)) and the National Committee for Quality Assurance (NCQA). This Measure is not a clinical
guideline and does not establish a standard of medical care, and has not been tested for all potential applications. The
Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg,
use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or
distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold,
licensed or distributed for commercial gain. Commercial uses of the Measure require a license agreement between the
user and the PCPI(R) or NCQA. Neither the American Medical Association (AMA), nor the former AMA-convened
Physician Consortium for Performance Improvement(R), PCPI, NCQA nor its members shall be responsible for any use
of the Measure. (C) 2018 National Committee for Quality Assurance and PCPI (R) Foundation. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code
sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or
accuracy of any CPT or other codes contained in the specifications.

CPT(R) contained in the Measure specifications is copyright 2004-2018 American Medical Association. LOINC(R)
copyright 2004-2018 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT(R))
copyright 2004-2018 International Health Terminology Standards Development Organisation. ICD-10 copyright 2018
World Health Organization. All Rights Reserved.

The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not
been tested for all potential applications.

THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
2019 Clinical Quality Measure Flow for Quality ID #418: NQF #0053: Osteoporosis Management in Women Who Had a Fracture Option 1

Start

Denominator

Patient Age at Date of Service 50-85 Years

No

Diagnosis Any Fracture as Listed in Denominator

Yes

Not Included in Eligible Population/Denominator

No

Encounter as Listed in Denominator (1/1/2019 thru 12/31/2019) Option 1

Denominator Exclusions

Yes

Patients Who Utilize Hospice Services Any Time During the Performance Period G9763 or Equivalent

No

Patients Who Had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months G9763 or Equivalent

Yes

No

Patients Age 65 or Older in Institutional Special Needs Plans (SNF) or Residing in Long-Term Care with POS Code 32, 33, 34, 35, or 54 Any Time During the Measurement Period G9558 or Equivalent

Yes

No

Multiple Performance

Include in Eligible Population/Denominator (75 Episodes) d1

Numerator

Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented

Yes

Data Completeness Met + Performance Met 3095F (20 Episodes) a1

No

Pharmacologic Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed

Yes

Data Completeness Met + Performance Met G8633 (10 Episodes) a2

No

Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed Reason Not Otherwise Specified

Yes

No

Data Completeness Met + Performance Not Met 3095F-SP (20 Episodes) c1

Pharmacologic Therapy for Osteoporosis Was Not Prescribed Reason Not Given

Yes

Data Completeness Met + Performance Not Met G8635 (10 Episodes) c2

No

Data Completeness Not Met Quality-Data Code Not Submitted (10 Episodes)

* See the posted Measure Specification for specific coding and instructions to submit this measure.

**While the Central Dual Energy X-Ray Absorptiometry (DXA) is the most common measurement for measuring bone mineral density (BMD), for the purposes of submitting this measure, spinal densitometry X-ray, ultrasonography for densitometry, C1 bone density axial and Peripheral Dual energy X-Ray Absorptiometry (DXA) would meet performance and the intent of the measure and 3095F would be submitted.

The measure contains 2 Submission Criteria, although as the Sample Calculation indicates, there is ONLY one data completeness and one performance rate for this measure.

NOTE: Submission Frequency Episode
2019 Clinical Quality Measure Flow for Quality ID #418: NQF #0053: Osteoporosis Management in Women Who Had a Fracture Option 2

**Denominator**

- **Patient Age at Date of Service 50-85 Years**
  - **Yes**
  - **Diagnosis Any Fracture as Listed in Denominator**
    - **Yes**
    - **Patient Age 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS Code 32, 33, 34, 54, or 56 Any Time During the Performance Period**
      - **Yes**
      - Denominator Exclusions
        - **Patients Who Utilize Hospice Services Any Time During the Performance Period G9765 or Equivalent**
          - **Yes**
          - **Patient Had a Bone Mineral Test in the Past Two Years or Received Osteoporosis Medication or Therapy in the Past 12 Months G9765 or Equivalent**
            - **Yes**
            - **Patient Had a Bone Mineral Test in the Past Two Years or Received Osteoporosis Medication or Therapy in the Past 12 Months G9765 or Equivalent**
              - **Yes**
              - **Patients Age 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS Code 32, 33, 34, 54, or 56 Any Time During the Performance Period G9938 or Equivalent**
                - **Yes**
                - **Preprocedure as Listed in Denominator (1/1/2019 thru 12/31/2019) Option 2**
                  - **Yes**
                  - Not Included in Eligible Population/Denominator*
                    - **No**
                    - **Diagnosis Any Fracture as Listed in Denominator**
                      - **No**
                      - **Procedure as Listed in Denominator (1/1/2019 thru 12/31/2019) Option 2**
                        - **Yes**
                        - Not Included in Eligible Population/Denominator*
                          - **No**
                          - **Data Completeness Not Met Quality-Data Code Not Submitted (10 Episodes)**

**Numerator**

- **Include in Eligible Population/Denominator (78 Episodes) d^2**
  - **Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented**
    - **Yes**
    - **Data Completeness Met + Performance Met 3036F (20 Episodes) a^3**
      - **Yes**
      - **Pharmacologic Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed**
        - **Yes**
        - **Data Completeness Met + Performance Met 36633 (10 Episodes) b^4**
          - **Yes**
          - **Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed Reason Not Otherwise Specified**
            - **Yes**
            - **Data Completeness Met + Performance NotMet 3065F-B (20 Episodes) c^3**
              - **Yes**
              - **Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given**
                - **Yes**
                - **Data Completeness Met + Performance NotMet 36635 (10 Episodes) c^4**

**Note**

* See the posted Measure Specification for specific coding and instructions to submit this measure.

**While the Central Dual-Energy X-Ray Absorptiometry (DXA) is the most common measurement for measuring bone mineral density (BMD), for the purposes of submitting this measure, spinal densitometry, X-ray, ultrasonography for densitometry, CT bone density axial and Peripheral Dual-energy X-Ray Absorptiometry (DXA) would meet performance and the intent of the measurement and 3036F would be submitted. This measure contains 2 Submission Criteria, although as the Sample Calculation indicates, there is ONLY one data completeness and one performance rate for this measure.**

**NOTE** Submission Frequency: Episode
2019 Clinical Quality Measure Flow for Quality ID #418: NQF #0053: Osteoporosis Management in Women Who Had a Fracture

SAMPLE CALCULATIONS:

Data Completeness:

\[
\text{Performance Rate} = \frac{\text{Numerator} \times \text{Denominator}}{\text{Numerator} \times \text{Denominator}} = \frac{60 \text{ episodes}}{120 \text{ episodes}} = 50.00\%
\]

Performance Rate:

\[
\text{Performance Rate} = \frac{\text{Performance Rate} \times \text{Denominator}}{\text{Performance Rate} \times \text{Denominator}} = \frac{120 \text{ episodes}}{140 \text{ episodes}} = 85.71\%
\]

* See the posted Measure Specification for specific coding and instructions to submit this measure.

**While the Central Dual Energy X-Ray Absorptiometry (DXA) is the most common measurement for measuring bone mineral density (BMD), for the purposes of submitting this measure, spinal densitometry X-ray, ultrasonography for densitometry, CT bone density axial and Peripheral Dual-energy X-Ray Absorptiometry (DXA) would meet performance and the intent of the measure and 3695F would be submitted.

This measure contains 2 Submission Criteria, although as the Sample Calculation indicates, there is ONLY one data completeness and one performance rate for this measure.

NOTE: Submission Frequency: Episode
2019 Clinical Quality Measure Flow Narrative for Quality ID #418 NQF #0053: Osteoporosis
Osteoporosis Management in Women Who Had a Fracture

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification.

Submission Criteria 1

1. Start with Denominator

2. Check Patient Age:
   a. If the Patient Age is 50 to 85 Years on Date of Service equals No during the performance period, do not include in Eligible Population. Stop Processing.
   b. If the Patient Age is 50 to 85 Years on Date of Service equals Yes during the performance period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Any Fracture as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis of Any Fracture as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Patients Who Utilize Hospice Services Any Time During the Performance Period.

5. Check Patients Who Utilize Hospice Services Any Time During the Performance Period:
   a. If Patients Who Utilize Hospice Services Any Time During the Performance Period equals No, proceed to check Patients Who Had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months.
   b. If Patients Who Utilize Hospice Services Any Time During the Performance Period equals Yes, do not include in Eligible Population. Stop Processing.

6. Check Patients Who Had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months:
   a. If Patients Who Had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals No, proceed to check Patients Age 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the measurement period.
   b. If Patients Who Had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals Yes, do not include in Eligible Population. Stop Processing.

7. Check Patients Age 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the measurement period.
a. If Patient Age is 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the measurement period equals No, include in Eligible Population

b. If Patient Age is 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the measurement period equals Yes, do not include in Eligible Population. Stop Processing.

8. Denominator Population:
   a. Denominator Population is all Eligible Episodes in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d1 equals 70 episodes in the Sample Calculation.

9. Start Numerator

10. Check Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented**:
   a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented** equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a1 equals 20 episodes in the Sample Calculation.
   c. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented** equals No, proceed to check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed.

11. Check Pharmacological Therapy for Osteoporosis (Other Than Minerals/Vitamins) Prescribed:
   a. If Pharmacological Therapy for Osteoporosis (Other Than Minerals/Vitamins) Prescribed equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter a2 equals 10 episodes in Sample Calculation.
   c. If Pharmacological Therapy for Osteoporosis (Other Than Minerals/Vitamins) Prescribed equals No, proceed to check Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reasons Not Otherwise Specified.

12. Check Central Dual-energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reasons Not Otherwise Specified:
   a. If Central Dual-energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reasons Not Otherwise Specified equals Yes, include in Data Completeness Met and Performance Not Met.
   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c1 equals 20 episodes in the Sample Calculation.
   c. If Central Dual-energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reasons Not Otherwise Specified equals No, proceed to check Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reasons Not Given.

13. Check Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given:
a. If Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter \( c^2 \) equals 10 episodes in the Sample Calculation.

c. If Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given equals No, proceed to check Data Completeness Not Met.

14. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 episodes have been subtracted from the Data Completeness Numerator in the Sample Calculation.
2019 Clinical Quality Measure Flow Narrative for Quality ID #418 NQF #0053:
Osteoporosis Management in Women Who Had a Fracture

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification.

Submission Criteria 2

1. Start with Denominator

2. Check Patient Age:
   a. If the Patient Age is 50 to 85 Years on Date of Service equals No during the performance period, do not include in Eligible Population. Stop Processing.
   b. If the Patient Age is 50 to 85 Years on Date of Service equals Yes during the performance period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Any Fracture as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis of Any Fracture as Listed in the Denominator equals Yes, proceed to check Procedure Performed.

4. Check Procedure Performed:
   a. If Procedure as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Procedure as Listed in the Denominator equals Yes, proceed to check Patients Who Utilize Hospice Services Any Time During the Performance Period.

5. Check Patients Who Utilize Hospice Services Any Time During the Performance Period:
   a. If Patients Who Utilize Hospice Services Any Time During the Performance Period equals No, proceed to check Patients Who Had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months.
   b. If Patients Who Utilize Hospice Services Any Time During the Performance Period equals Yes, do not include in Eligible Population. Stop Processing.

6. Check Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months:
   a. If Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals No, proceed to check Patients Age 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 Any Time During the Performance Period.
   b. If Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals Yes, do not include in Eligible Population. Stop Processing.

7. Check Patients Age 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the performance period
a. If Patient Age is 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the performance period equals No, include in Eligible Population.

b. If Patient Age is 65 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 any time during the performance period equals Yes, do not include in Eligible Population. Stop Processing.

8. Denominator Population:
   a. Denominator Population is all Eligible Episodes in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter \( d^2 \) equals 70 episodes in the Sample Calculation.

9. Start Numerator

10. Check Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented:
    a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented\(^*\) equals Yes, include in Data Completeness Met and Performance Met.
    b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter \( a^3 \) equals 20 episodes in Sample Calculation.
    c. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented\(^*\) equals No, proceed to check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed.

11. Check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed:
    a. If Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed equals Yes, include in Data Completeness Met and Performance Met.
    b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter \( a^4 \) equals 10 episodes in the Sample Calculation.
    c. If Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed equals No, proceed to check Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified.

12. Check Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified:
    a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified equals Yes, include in Data Completeness Met and Performance Not Met.
    b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter \( c^3 \) equals 20 episodes in the Sample Calculation.

13. Check Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given:
a. If Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c* equals 10 episodes in the Sample Calculation.

c. If Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given equals No, proceed to check Data Completeness Not Met.

14. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 episodes have been subtracted from the Data Completeness Numerator in Sample Calculation.

<table>
<thead>
<tr>
<th>Data Completeness—</th>
<th>Performance Met ((a^<em>) + (a^</em>) + (a^*) + 60 episodes)</th>
<th>Performance Not Met ((c^<em>) + (c^</em>) + (c^*) + 60 episodes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>120 episodes</td>
<td>85.71%</td>
</tr>
<tr>
<td>Eligible Population</td>
<td>140 episodes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Performance Rate—</th>
<th>Performance Met ((a^<em>) + (a^</em>) + (a^*) + 60 episodes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60 episodes</td>
</tr>
<tr>
<td>Data Completeness</td>
<td>120 episodes</td>
</tr>
</tbody>
</table>